Companies › Oncomatryx Biopharma
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OMTX705 anti-FAP antibody-drug conjugate | FAP | Phase 1 | Advanced Solid Tumor; Pancreatic Adenocarcinoma Metastatic | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05547321 | OMTX705 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT07377045 | OMTX705 | Phase 1 | Pancreatic Adenocarcinoma Metastatic | Oncology | Mar 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.